Ultimovacs ASA Market Cap ($52.14 Million)
Market Cap & Net Worth: Ultimovacs ASA (ULTI)
Ultimovacs ASA market cap. Ultimovacs ASA (OL:ULTI) has a market capitalization of $52.14 Million (Nkr495.45 Million) as of November 1, 2026. Listed on the OL stock exchange, this Norway-based company holds position #21563 globally and #195 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ultimovacs ASA's stock price Nkr14.40 by its total outstanding shares 34406100 (34.41 Million). Also see ULTI cash flow conversion for how efficiently the company converts equity into cash flow.
Ultimovacs ASA Market Cap History (2019–2025)
Ultimovacs ASA market cap history from 2019 to 2025. Data shows change from $141.20 Million to $52.14 Million (-10.14% CAGR). Check ULTI stock price for real-time trading data and today's change.
Ultimovacs ASA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ultimovacs ASA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Ultimovacs ASA (ULTI) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ULTI by Market Capitalization
Companies near Ultimovacs ASA in the global market cap rankings as of November 1, 2026. Also see Ultimovacs ASA total assets for a full breakdown of the balance sheet.
Key companies related to Ultimovacs ASA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Ultimovacs ASA (2019–2025)
Market capitalization of Ultimovacs ASA from 2019 to today. Between 2019 and today, Ultimovacs ASA's market cap moved from $141.20 Million to $ 52.14 Million, with a yearly change of -10.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | Nkr52.14 Million | +518.03% |
| 2024 | Nkr8.44 Million | -98.10% |
| 2023 | Nkr444.60 Million | +11.64% |
| 2022 | Nkr398.26 Million | -2.48% |
| 2021 | Nkr408.39 Million | +41.00% |
| 2020 | Nkr289.64 Million | +105.13% |
| 2019 | Nkr141.20 Million | -- |
End of Day Market Cap According to Different Sources
On May 1st, 2026 the market cap of Ultimovacs ASA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $52.14 Million USD |
| MoneyControl | $52.14 Million USD |
| MarketWatch | $52.14 Million USD |
| marketcap.company | $52.14 Million USD |
| Reuters | $52.14 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ultimovacs ASA
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.